Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002878 (
hemolytic anemia
)
7,530
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Giant cell hepatitis (CGH) with autoimmune
haemolytic anaemia
(AHA) is a distinct entity with an aggressive course. Immunosuppression may help early disease. A case is reported of a child with
GCH
and AHA with early disease recurrence after liver transplantation for end stage liver disease.
...
PMID:Liver transplant for giant cell hepatitis with autoimmune haemolytic anaemia. 937 Sep 7
Giant cell hepatitis with autoimmune hemolytic anemia (GCH-AHA) is a rare autoimmune disease of infancy characterized by severe liver disease associated with Coombs-positive
hemolytic anemia
. We recently showed that
GCH
-AHA is probably caused by a humoral immune mechanism. Such data support the use of rituximab, an anti-CD-20 monoclonal antibody specifically targeting B lymphocytes, as a treatment for
GCH
-AHA. We describe here the detailed clinical evolution of 4 children with
GCH
-AHA who showed a complete response to rituximab. All patients shared a severe course of the disease with poor control on standard and aggressive immunosuppression. Rituximab was well tolerated, and no side effects or infections were registered. Several doses were needed to induce remission, and 5 to 11 additional maintenance injections were necessary in the 2 more severe cases. Weaning from corticosteroids was achieved in all subjects. A steroid-sparing effect was noted in the 3 children who started rituximab early in the course of the disease. Overall, we show here that there is a strong rationale for treating
GCH
-AHA with rituximab. Early treatment could reduce the use of corticosteroids. Nevertheless, short-term steroids should be initially associated with rituximab to account for autoantibodies' half-life. Repeated injections are needed to treat and prevent relapses, but the best frequency and duration of treatment remain to be defined.
...
PMID:Anti-CD20 treatment of giant cell hepatitis with autoimmune hemolytic anemia. 2520 97